GenomOncology Receives Investment from TriStar Technology Ventures

GenomOncology, a Westlake, Ohio-based developer of technology that translates next generation sequencing data for clinicians and researchers, received an investment from TriStar Technology Ventures.

The amount of the funding was not disclosed. In conjunction with the funding, John Doulis, CIO of TriStar’s partner fund, MedCare Investment Funds, joined GenomOncology’s board of directors.

Led by Manuel J. Glynias, President and CEO, GenomOncology provides technology and services for the interactive analysis and interpretation of Next Generation Sequencing (NGS) data,
The company has developed two proprietary software platforms that streamline the use of NGS in medicine and research:
– GO Clinical Workbench™ for the clinical laboratory, a decision support tool with a workflow that takes raw data from the sequencer and translates the specific molecular profile of each patient’s tumor genome into an actionable clinical report.
– GenomAnalytics™ for research applications, which allows scientists to analyze hundreds of genomes simultaneously to look for causal variants.

For the clinical laboratory, the platform is configured to each client’s specific needs with clinical systems (LIMS, EMR, etc.) integration, setting of quality control and annotation parameters, and design of the resultant clinical report.
For researchers, the platform is updated on a monthly basis, adding new features and functions based on individualized research interests and use. In both environments, GenomOncology provides onsite experts in bioinformatics and genomics to leverage the platform to support each client’s current and future needs.



Join the discussion